You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞通窩輪》瑞通認股證牛熊證恆指彈近400點試10天線南中升1%重上15元恆指牛69235熊67823/南中牛50254熊68431/騰訊購22285沽29374
阿思達克 07-11 11:05

聯儲局主席鮑威爾在國會聽證會上暗示最快本月底減息,帶動道指隔晚升76點(或0.3%),收報26860點。

恆指昨升88點(或0.3%),報28204點,結束5連跌走勢。今早升超過300點,曾逼近28600點。恆指好倉(牛證及認購權證)昨淨流出逾3400萬港元(下同);恆指淡倉(熊證及認沽權證)同日淨流入逾4500萬元,反映投資者傾向持淡倉過夜看跌。昨日恆指牛證街貨重貨區為收回價28000至28078點,而熊證街貨重貨區為收回價29000至29099點。

中美貿易戰稍為緩和後,A股近日再度轉弱,上證綜合指數連跌3日,下試2900點水平。國家統計局昨公布上月居民消費價格指數(CPI)按年升2.7%,符合市場預期。有大行預期內地今年全年通脹2.5%,但在經濟增長出現放緩下,物價回升也不會影響人行寬鬆的貨幣政策方向。其他影響A股氣氛和後市走勢的因素還包括中國科創板首批25家公司將於今月22日正式上市交易,以及MSCI第二批A股納入比例將於8月生效。南方A50(02822)昨微升收市,由今月初15.42元高位回落至昨日收市計,南方A50累跌3.5%,現於10天和20天線之間爭持上落。今早其走勢靠穩,一度升穿15元的10天線阻力。昨有51萬元淨流出其好倉,淡倉同日則有37萬元淨流入。

醫藥股昨走高,升逾4%的石藥(01093)為昨日表現最好藍籌,以近全日高位12.7元收市,一舉收復10天和20天線,並終止四連跌。有大行報告指儘管石藥旗下藥品歐來寧被列入今月1日發布的首份全國重點監控目錄,但預計集團目前重磅藥品的市場滲透率可進一步提高及今年下半年新藥品銷售提升,輕微上調股份目標價。石藥今早再升近2%,向上挑戰13元。昨分別有47萬元和9萬元淨流入其好倉和淡倉。

投資者繼續憧憬同股不同權股份有機會本月納入港股通,屆時北水可透過港股通買賣美團(03690)。另一邊廂,美團大股東兼聯合創始人王興近日申報,已獲相關財務機構批准,在特定事件發生後可出售最多1.22億股A類股。美團發言人指相關措施為股權質押貸款,並非減持股份。美團股價連跌4個交易日,累跌3.6%,昨失守10天線。股份今早繼續整固,跌2%,回至66元之水平,近期高位70.5元料阻力不小,下一級支持留意約65.28元的20天線。昨分別有287萬元和2萬元淨流入其好倉和淡倉。

上周美國原油庫存減幅多過市場預期,油價隔晚急升超過4%。近期弱勢的中石化(00386),昨以全日低位5.1元收市,連跌3個交易日,今早升近3%,嘗試企穩10及20天線(同約5.23元),支持留意一個月低位5.01元。昨分別有87萬元和4萬元淨流入其好倉和淡倉。

瑞通相關認股證之選擇:

騰訊輕微價外、短期購22285,行使價:375.2元,2019年9月到期,實際槓桿:12.7倍

騰訊貼價、短期沽29374,行使價:350元,2019年10月到期,實際槓桿:9.7倍

南中A50輕微價外、長期購29370,行使價:16.5元,2020年7月到期,實際槓桿:6.2倍

南中A50價內、中短期沽17503,行使價:15元,2019年11月到期,實際槓桿:6.9倍

石藥輕微價外、中短期購20531,行使價:13.88元,2019年11月到期,實際槓桿:5.3倍

美團貼價、中短期購29719,行使價:70元,2019年12月到期,實際槓桿:5倍

中化輕微價外、中短期購18065,行使價:5.7元,2019年10月到期,實際槓桿:11.7倍

中化貼價、中短期沽18345,行使價:5元,2019年12月到期,實際槓桿:6.7倍

新地輕微價外、中年期購20643,行使價:143.8元,2020年1月到期,實際槓桿:9.7倍

新地輕微價外、中短期沽16143,行使價:126.8元,2019年11月到期,實際槓桿:10.3倍

瑞通相關牛熊證之選擇:

恆指牛證69235,收回價:28010點,槓桿比率:40.2倍

恆指熊證67823,收回價:29090點,槓桿比率:39.1倍

騰訊牛證69274,收回價:346.1元,槓桿比率:19.8倍

騰訊熊證50427,收回價:375.3元,槓桿比率:17.8倍

南中A50牛證50254,收回價:14.18元,槓桿比率:15.6倍

南中A50熊證68431,收回價:15.99元,槓桿比率:13倍

石藥牛證50345,收回價:11.8元,槓桿比率:6.1倍

美團牛證59429,收回價:54.8元,槓桿比率:4.3倍

中化牛證60406,收回價:4.8元,槓桿比率:9.3倍

中化熊證65481,收回價:5.49元,槓桿比率:9.3倍 重要風險通知

本結構性產品並無抵押品。

結構性產品之價格一般可急升亦可急跌,有可能損失結構性產品之全部或重大部分購買價,閣下對此應有所準備。

閣下投資前應了解產品風險,如有需要應諮詢專業建議。~ 重要聲明:

以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account